Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

Clinical trial NCT02306850 · COMPLETED

Trial details

NCT number: NCT02306850
Sponsor: St. Louis University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Malignant Neoplasm Melanoma Metastatic Melanoma Stage IV Melanoma Stage III Melanoma

Start date: 2015-01-01
Primary completion: 2018-06-08
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.